Back to Search Start Over

Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis.

Authors :
Jenkins, David J. A.
Josse, Andrea R.
Beyene, Joseph
Dorian, Paul
Burr, Michael L.
LaBelle, Roxanne
Kendall, Cyril W. C.
Cunnane, Stephen C.
Source :
Canadian Medical Association Journal (CMAJ); 1/15/2008, Vol. 178 Issue 2, p157-164, 8p, 4 Diagrams, 1 Chart
Publication Year :
2008

Abstract

Background: A recent Cochrane meta-analysis did not confirm the benefits of fish and fish oil in the secondary prevention of cardiac death and myocardial infarction. We performed a meta-analysis of randomized controlled trials that examined the effect of fish-oil supplementation on ventricular fibrillation and ventricular tachycardia to determine the overall effect and to assess whether heterogeneity exists between trials. Methods: We searched electronic databases (MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials, CINAHL) from inception to May 2007. We included randomized controlled trials of fish-oil supplementation on ventricular fibrillation or ventricular tachycardia in patients with implantable cardioverter defibrillators. The primary outcome was implantable cardioverter defibrillator discharge. We calculated relative risk [RR] for outcomes at 1-year follow-up for each study. We used the DerSimonian and Laird randomeffects methods when there was significant heterogeneity between trials and the Mantel-Hanzel fixed-effects method when heterogeneity was negligible. Results: We identified 3 trials of 1-2 years' duration. These trials included a total of 573 patients who received fish oil and 575 patients who received a control. Meta-analysis of data collected at 1 year showed no overall effect of fish oil on the relative risk of implantable cardioverter defibrillator discharge. There was significant heterogeneity between trials. The second largest study showed a significant benefit of fish oil (relative risk [RR] 0.74, 95% confidence interval [CI] 0.56-0.98). The smallest showed an adverse tendency at 1 year (RR 1.23, 95% CI 0.92-1.65) and significantly worse outcome at 2 years among patients with ventricular tachycardia at study entry (log rank p = 0.007). Conclusion: These data indicate that there is heterogeneity in the response of patients to fish-oil supplementation. Caution should be used when prescribing fish-oil supplementation for patients with ventricular tachycardia. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
08203946
Volume :
178
Issue :
2
Database :
Complementary Index
Journal :
Canadian Medical Association Journal (CMAJ)
Publication Type :
Academic Journal
Accession number :
28793639
Full Text :
https://doi.org/10.1503/cmaj.070261